• Mashup Score: 0
    Chemoimmunotherapy Regimens Improve Long-term Outcomes in Small Cell Lung Cancer - 1 year(s) ago

    Stephen V. Liu, MD, discusses the effect of the FDA approval of atezolizumab on the development of other chemoimmunotherapy regimens and ongoing efforts to expand and individualize treatment options in small cell lung cancer.

    Source: OncLive
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of OncLive
      OncLive

      .@StephenVLiu, of @LombardiCancer, discusses the effect of the FDA approval of #atezolizumab on the development of other chemoimmunotherapy regimens and ongoing efforts to expand and individualize treatment options in SCLC. #lcsm https://t.co/riHZ1PRDzq https://t.co/Uw41ZEGPn8

  • Mashup Score: 0
    FDA Approves Atezolizumab for Alveolar Soft Part Sarcoma - 1 year(s) ago

    The FDA has approved atezolizumab (Tecentriq) for adult and pediatric patients aged 2 years and older with unresectable or metastatic alveolar soft part sarcoma.

    Source: OncLive
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of OncLive
      OncLive

      ICYMI: The @US_FDA has approved #atezolizumab (#Tecentriq) for adult and pediatric patients aged 2 years and older with unresectable or metastatic alveolar soft part sarcoma. #scmsm https://t.co/QX2hVgq21O https://t.co/elw6ZdtQJH

  • Mashup Score: 0
    FDA Approves Atezolizumab for Alveolar Soft Part Sarcoma - 1 year(s) ago

    The FDA has approved atezolizumab (Tecentriq) for adult and pediatric patients aged 2 years and older with unresectable or metastatic alveolar soft part sarcoma.

    Source: OncLive
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of EladSharonMD
      EladSharonMD

      .⁦@FDAOncology⁩ Approves #Atezolizumab for Alveolar Soft Part Sarcoma, or ASPS! Proud to say that I was involved in this ⁦@theNCI⁩ from start to this finish line. Thanks to ⁦@genentech⁩, @NCIResearchCtr⁩, & ⁦@NCItreatment⁩ https://t.co/o0b7QjEG15

  • Mashup Score: 1
    Wolters Kluwer Health - 1 year(s) ago

    JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…

    Source: lww.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of OncologyTimes
      OncologyTimes

      An interim analysis of the Phase III IMpower010 #clinicaltrial of #adjuvant treatment with #atezolizumab following #surgery and #chemotherapy shows a trend toward overall survival improvement in patients compared with best supportive care: https://t.co/pOYq94UswY https://t.co/FIcRiPMgSI

  • Mashup Score: 0
    Roche withdraws atezolizumab indication for urothelial carcinoma - 1 year(s) ago

    Roche voluntarily withdrew atezolizumab’s indication in the United States for the treatment of adults with locally advanced or metastatic urothelial carcinoma.The indication applied to use of atezolizumab (Tecentriq, Genentech) — an anti-PD-L1 antibody — by patients who are ineligible for cisplatin-containing chemotherapy and whose tumors express PD-L1, or those ineligible for

    Source: www.healio.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of HemOncToday
      HemOncToday

      Roche withdraws atezolizumab indication for urothelial carcinoma. https://t.co/9RIzdadj7P #atezolizumab #UrothelialCarcinoma #Tecentriq @genentech #HemOnc #OncAlert #MedEd

Load More